Fas/FasL系统在人子宫内膜增生过长和子宫内膜癌中的表达

目的：探讨Fas和Fas配体（FasL）在人子宫内膜增生过长和子宫内膜癌发病中的作用．方法：采用免疫组化链霉菌抗生物素蛋白过氧化物酶染色法（SP法）检测加例子宫内膜增生过长的异位内膜与18例子宫内膜癌内膜中Fas和FasL蛋白的表达；采用原位杂交方法检测FasLmRNA水平．设正常子宫内膜25例为对照组．结果：Fas蛋白在正常子宫内膜的阳性表达率为68％，在子宫内膜增生过长与子宫内膜癌组的阳性表达率分别为58％和22％，差异具有统计学意义（P〈0．05）．FasL蛋白在子宫内膜增生过长与子宫内膜癌组中的阳性表达率分别为68％和94％，明显高于对照组32％，差异具有统计学意义（P〈0．05）．FasLmRNA的表达强度在子宫内膜增生过长与子宫内膜癌组亦明显高于对照组，差异具有统计学意义（P〈0．05）．结论：Fas与FasL蛋白表达失调，可能是子宫内膜增生过长的发病机制之一，对子宫内膜癌组织逃避免疫系统监视具有重要作用．

Expression of Fas/FasL in human endometrial hyperplasia and endometrial carcinoma

AIM: To investigate the roles of Fas and Fas ligand(FasL) in the pathogenesis of endometrial hyperplasia and endometrial carcinoma. METHODS: Immunohistochemical SP method was employed to detect the expressions of Fas and FasL in endometrial hyperplasia(40 cases), endometrial carcinoma (18 cases) and normal controls(25 cases). In situ hybridization technique was used to investigate the lever of FasL mRNA. RESULTS: The expression of Fas was lower in endometrial hyperplasia(58%) and endometrial carcinoma (22%), when compared to the controls(68%, P<0.05). However, the expression of FasL was higher in endometrial hyperplasia(68%) and endometrial carcinoma (94%) as compared to the controls(32%, P<0.05). Results of in situ hybridization showed that the positive rates of FasL mRNA in endometrial hyperplasia and endometrial carcinoma were both higher than that in normal endometrium(P<0.05). CONCLUSION: The abnormal expression of Fas/FasL might be one of the pathogenesis factors for endometrial hyperplasia and immune escape for endometrial carcinoma, which may play an important role in the pathophysiology of the diseases.